Watchlist · 75/100Sep 29, 7:44 AM EDT
Iovance Lifts 2026 Revenue Guidance Above Wall Street Estimates on Strong Amtagvi and Proleukin Demand
IOVA
Iovance Biotherapeutics raised its full-year 2026 revenue guidance to $410M-$420M, up from $350M-$370M, surpassing the $402.8M analyst consensus. The company attributed the increase to stronger U.S. demand for its cancer therapies Amtagvi and Proleukin. The up…
- ▹Raised 2026 revenue guidance above consensus, signaling strong commercial demand for Amtagvi and Proleukin
- ▹Commercial-stage cell therapy platform with differentiated TIL technology, but manufacturing and regulatory risks remain
Watchlist · 70/100Sep 29, 2:47 PM EDT
Iovance Biotherapeutics Shares Surge Over 30% as Raised Revenue Guidance Tops Consensus
IOVA
Iovance Biotherapeutics raised its full-year revenue outlook above analyst consensus, implying nearly 60% year-over-year growth. The cell therapy developer's stock jumped more than 30% on Tuesday, reaching its highest level since 2024, as analysts cheered the…
- ▹Revenue guidance raise to ~60% YoY growth signals strong commercial traction for TIL therapy
- ▹Analyst cheer and 30% stock jump reflect positive momentum, but single-asset risk and manufacturing complexity remain
Neutral · 58/100Sep 29, 4:19 AM EDT
AstraZeneca's $2B Bet on Summit Therapeutics Wins Analyst Backing; SMMT Jumps 23%
AZNSMMT
AstraZeneca announced a $2 billion investment in Summit Therapeutics to collaborate on a new cancer drug, sending SMMT shares up 23% while AZN gained 2% premarket. Analysts from JPMorgan and Citi have endorsed the deal, signaling confidence in the partnership'…
- ▹AstraZeneca's $2B investment validates Summit's cancer drug but no regulatory or clinical data disclosed
- ▹Stock gains reflect sentiment, not fundamental progress; single-asset biotech with limited commercial stage
High Risk · 47/100Sep 29, 5:39 AM EDT
Pharming CEO Fabrice Chouraqui Exits Abruptly
PHAR
Pharming announced that CEO Fabrice Chouraqui is stepping down immediately by mutual agreement with the board. The departure follows discussions about executing the company's strategic priorities for its next phase. This sudden leadership change introduces unc…
- ▹Abrupt CEO departure signals strategic uncertainty and potential internal discord.
- ▹No operational or pipeline update; pure governance news with no positive catalysts.
High Risk · 45/100Sep 29, 4:42 PM EDT
Pyxis Oncology Kicks Off Stock Offering to Fund Phase 3 Cancer Trial, Shares Drop
PYXS
Pyxis Oncology announced a registered public offering of common stock and warrants to raise funds for its lead cancer program, MICVO, including a planned Phase 3 trial. The news sent PYXS shares tumbling, as investors reacted to potential dilution. The offerin…
- ▹Dilutive equity offering for a single-asset Phase 3 program signals cash burn and financing risk.
- ▹No regulatory, commercial, or manufacturing differentiation; high uncertainty.
High Risk · 45/100Sep 29, 12:35 PM EDT
Invivyd Shares Tumble 13% as COVID Antibody Trial Data Delayed Despite Positive Late-Stage Results
IVVDPFEBNTX
Invivyd announced positive late-stage trial results for its COVID-19 antibody therapy VYD2311, but simultaneously delayed the timeline for another pivotal trial. The delay overshadowed the positive data, sending shares down over 13% on Tuesday. Investors are c…
- ▹Delayed pivotal trial timeline for VYD2311 creates regulatory and development uncertainty
- ▹Single-asset COVID antibody with limited platform differentiation and no commercial revenue
High Risk · 45/100Sep 29, 9:13 AM EDT
Immix Biopharma Stock Climbs on Positive Mid-Stage Data for AL Amyloidosis Therapy Despite $125M Offering
IMMX
Immix Biopharma reported positive interim data from a Phase 2 trial of NXC-201 in AL amyloidosis, a rare and life-threatening disorder. The news lifted IMMX shares in premarket trading even as the company announced a $125 million stock offering. Investors will…
- ▹Single-asset micro-cap with only mid-stage data and no regulatory designations
- ▹Recent $125M stock offering signals dilution risk and short runway
High Risk · 42/100Sep 29, 4:22 PM EDT
Larimar Therapeutics Taps John Harlow as President and COO
LRMR
Larimar Therapeutics (LRMR) named John Harlow as President and Chief Operating Officer, effective September 29, 2026. Harlow brings over 25 years of commercial and business development experience, most recently as CCO of Esperion Therapeutics. The appointment…
- ▹Executive appointment only, no pipeline or regulatory update
- ▹Clinical-stage single-asset company with no commercial revenue
High Risk · 40/100Sep 29, 8:08 AM EDT
Lantern Pharma Secures Up to $8M in Registered Direct Offering
LTRN
Lantern Pharma (LTRN) has agreed to sell 3.66 million shares at $1.09 per share in a registered direct offering, raising up to $8 million. The capital infusion provides funding for the company's pipeline and operations, but the discounted pricing may signal ne…
- ▹Dilutive registered direct offering at $1.09/share signals cash need and weak balance sheet
- ▹No regulatory, clinical, or commercial catalysts in the news; pure financing event
High Risk · 40/100Sep 29, 7:33 AM EDT
Immix Biopharma Secures $125M in Stock Offering to Advance NXC-201
IMMX
Immix Biopharma priced an underwritten offering of 11.36 million shares at $11 per share, expecting gross proceeds of $125 million. The company will use the net proceeds primarily to fund development of its lead candidate NXC-201, a CAR-T therapy for relapsed/…
- ▹Single-asset micro-cap (NXC-201) with no regulatory or commercial validation
- ▹Heavy dilution from $125M offering and prior executive scandal weigh on narrative
High Risk · 37/100Sep 29, 9:36 AM EDT
Liminatus Pharma Clears Nasdaq Minimum Bid Price Hurdle
LIMNLIMNW
Liminatus Pharma (LIMN) announced on Tuesday that it has regained compliance with Nasdaq's minimum bid price requirement. The company had received a notice on January 15, 2026, after its stock closed below the $1 threshold. Regaining compliance removes the imm…
- ▹Pure listing-compliance news with no operational or clinical update
- ▹Micro-cap with prior Nasdaq deficiency, signaling financial distress and dilution risk
High Risk · 37/100Sep 29, 7:56 AM EDT
uniQure Shares Plummet Over 50% on Updated AMT-130 Data for Huntington's Disease
QURE
uniQure released updated Phase 1/2 trial data for its gene therapy AMT-130 in Huntington's disease, a rare neurodegenerative disorder. The stock plunged more than 50% in premarket trading as investors reacted negatively to the results. This sharp decline highl…
- ▹Updated Phase 1/2 data for AMT-130 triggered a >50% stock plunge, signaling serious efficacy/safety concerns and likely FDA setback.
- ▹Single-asset gene therapy with no commercial product, no partnership, and high dilution risk after major data disappointment.
High Risk · 28/100Sep 29, 7:13 AM EDT
Aldeyra to Challenge FDA Rejection of Dry Eye Drug Reproxalap
ALDX
Aldeyra Therapeutics will file a formal dispute resolution request asking the FDA's Office of New Drugs to reconsider its rejection of reproxalap for dry eye disease. The appeal seeks to overturn the Complete Response Letter, potentially reviving the drug's pa…
- ▹FDA rejection of reproxalap triggers appeal, severe regulatory setback
- ▹Single-asset micro-cap with no commercial product and high uncertainty